|
199 Companies |
|
329 Products |
|
329 Products |
|
164 Mechanisms of Action |
|
13 Trials |
|
3299 News |
|
| «12...56575859606162636465666768 |
- | lestaurtinib (CEP-701) / Teva, Kyowa Kirin
Trial completion: Open-Label Study of Oral CEP-701 (Lestaurtinib) in Patients With Polycythemia Vera or Essential Thrombocytosis (clinicaltrials.gov) - Aug 22, 2011
P2, N=39, Completed, Sponsor: Cephalon
Active, not recruiting --> Completed
- Enrollment closed: Collection of Patient-Reported Symptoms and Performance Status Via the Internet (clinicaltrials.gov) - Aug 22, 2011
P=N/A, N=300, Active, not recruiting, Sponsor: Cancer and Leukemia Group B
Active, not recruiting --> Completed Recruiting --> Active, not recruiting
- lenalidomide / Generic mfg.
New P1 trial: REVALLO: Lenalidomide After Reduced-intensity Allogeneic Stem Cell Transplantation for Relapsed Multiple Myeloma (clinicaltrials.gov) - Aug 21, 2011
P1, N=13, Recruiting, Sponsor: University Hospital, Bordeaux
- ||||| Inrebic (fedratinib) / BMS
New P2 trial: Study With SAR302503 in Patients With Polycythemia Vera or Essential Thrombocythemia (clinicaltrials.gov) - Aug 18, 2011
P2, N=90, Active, not recruiting, Sponsor: Sanofi
- | Calsed (amrubicin) / Sumitomo Pharma, BMS
Enrollment open, Combination therapy: Phase 1-2 Amrubicin in Combo With Lenalidomide + Weekly Dexamethasone in Relapsed/Refractory Multiple Myeloma (clinicaltrials.gov) - Aug 18, 2011
P1/2, N=42, Recruiting, Sponsor: Michaela Liedtke
Recruiting --> Active, not recruiting Not yet recruiting --> Recruiting
- bortezomib / Generic mfg., pegylated liposomal doxorubicin / Generic mfg.
Trial termination: Alternative Schedule of Velcade/Dexamethasone Plus Doxil for Patients With Multiple Myeloma (clinicaltrials.gov) - Aug 17, 2011
P2, N=32, Terminated, Sponsor: Accelerated Community Oncology Research Network
Not yet recruiting --> Recruiting Completed --> Terminated; Study was closed to enrollment when it became clear that enrollment was too slow to complete full enrollment target within time frame allowed.
- Rituxan (rituximab) / Roche
New P2 trial: Lenalidomide With or Without Rituximab in Treating Patients With Progressive or Relapsed Chronic Lymphocytic Leukemia, Small Lymphocytic Lymphoma, Prolymphocytic Leukemia, or Non-Hodgkin Lymphoma Previously Treated With Donor Stem Cell Transplant (clinicaltrials.gov) - Aug 16, 2011
P2, N=3, Terminated, Sponsor: Fred Hutchinson Cancer Research Center
- | Kogenate FS liposome (octocog alfa (pegylated)) / Recoly, Bayer
Trial termination: BAY79-4980 Compared to rFVIII-FS in Previously Treated Patients With Severe Hemophilia A (clinicaltrials.gov) - Aug 15, 2011
P2, N=143, Terminated, Sponsor: Bayer
Completed --> Terminated; Study was closed to enrollment when it became clear that enrollment was too slow to complete full enrollment target within time frame allowed. Completed --> Terminated
- | Arzerra (ofatumumab) / Novartis, Genmab
Enrollment closed: A Phase II Trial of Ofatumumab in Subjects With Waldenstrom's Macroglobulinemia (clinicaltrials.gov) - Aug 11, 2011
P2, N=37, Active, not recruiting, Sponsor: GlaxoSmithKline
Completed --> Terminated Recruiting --> Active, not recruiting
- | samalizumab (ALXN 6000) / The Leukemia & Lymphoma Society, AstraZeneca
Trial completion: Safety and Dose Ranging Study of Samalizumab to Treat Relapsing or Refractory CLL or MM (clinicaltrials.gov) - Aug 11, 2011
P1/2, N=26, Completed, Sponsor: Alexion Pharmaceuticals
Recruiting --> Active, not recruiting Active, not recruiting --> Completed
- Rituxan (rituximab) / Biogen, Zenyaku Holdings, Roche
Trial completion: Rituximab and Dexamethasone in Treating Patients With Low-Grade Non-Hodgkin Lymphoma (clinicaltrials.gov) - Aug 11, 2011
P2, N=55, Completed, Sponsor: Fred Hutchinson Cancer Research Center
Active, not recruiting --> Completed Active, not recruiting --> Completed
- Trial termination: Study of Multiple Myeloma Patients Relapsing or Progressing After Autologous Transplantation on Total Therapy 2 (clinicaltrials.gov) - Aug 10, 2011
P3, N=5, Terminated, Sponsor: University of Arkansas
Active, not recruiting --> Completed Completed --> Terminated; low accrual
- | glycoPEGylated factor VIIa (N7-GP) / Novo Nordisk
Trial completion: Investigating Safety and Pharmacokinetics of 2 Different Single Doses of NNC128-0000-2011 in Haemophilia A or B Patients (clinicaltrials.gov) - Aug 10, 2011
P1, N=15, Completed, Sponsor: Novo Nordisk
Completed --> Terminated; low accrual Active, not recruiting --> Completed
- bortezomib / Generic mfg.
Trial completion: UARK 2005-05, Coagulation-Related Effects of Velcade Treatment in Patients With Relapsed or Refractory Multiple Myeloma (clinicaltrials.gov) - Aug 10, 2011
P=N/A, N=11, Completed, Sponsor: University of Arkansas
Active, not recruiting --> Completed Terminated --> Completed
- ||||| Enrollment closed: American Ginseng in Treating Patients With Fatigue Caused by Cancer (clinicaltrials.gov) - Aug 9, 2011
P3, N=360, Active, not recruiting, Sponsor: North Central Cancer Treatment Group
Terminated --> Completed Recruiting --> Active, not recruiting
- Enrollment change: Vertebral Augmentation With Kyphoplasty vs Nonsurgical Mgmt for Vertebral Body Compression Fractures (clinicaltrials.gov) - Aug 8, 2011
P=N/A, N=0, Withdrawn, Sponsor: H. Lee Moffitt Cancer Center and Research Institute
Recruiting --> Active, not recruiting N=30 --> 0
- NovoSeven (eptacog alfa) / Novo Nordisk
Enrollment closed, Observational data: Observational Study on Safety and Efficacy of NovoSeven® in Subjects With Congenital FVII Deficiency (clinicaltrials.gov) - Aug 8, 2011
P=N/A, N=36, Active, not recruiting, Sponsor: Novo Nordisk
N=30 --> 0 Enrolling by invitation --> Active, not recruiting
- ||||| balixafortide (POL 6326) / Spexis
New P1/2 trial, Metastases: Safety and Efficacy of POL6326 for Mobilization/Transplant of Sibling Donor in Patients With Hematologic Malignancies (clinicaltrials.gov) - Aug 8, 2011
P1/2, N=60, Recruiting, Sponsor: Polyphor Ltd.